Next-Generation Immunotherapy to Overcome Tumor Resistance

Description

This technology is a next-generation oncolytic virus (OV) designed to address the critical challenge of tumor resistance in cancer therapy. Built on the vesicular stomatitis virus (VSV) platform, this engineered OV is capable of inducing strong, tumor-selective cell death even in apoptosis-resistant cancers.

In preclinical studies, this technology significantly reduced tumor volume in breast and pancreatic cancer models and showed promising results when combined with immune checkpoint inhibitors. By modifying the tumor microenvironment and promoting immune cell infiltration, this technology sets a new standard for efficacy and synergy in cancer immunotherapy.

Cancer remains one of the most urgent global health challenges, with 20 million new cases and 9.7 million deaths reported worldwide in 2022. According to the Global Cancer Observatory, these numbers are projected to rise to 33 million cases and 18.2 million deaths by 2050. Approximately 1 in 5 people will develop cancer in their lifetime.

Benefits

• Overcomes Tumor Resistance: Specifically addresses resistance to OV-induced apoptosis, enhancing cancer cell susceptibility to treatment.
• Enhanced Efficacy: Demonstrated up to 85% tumor volume reduction in preclinical models after a single dose.
• Immune System Activation: Converts immunosuppressive tumor environments into immune-reactive ones by reducing MDSCs and M2 macrophages and increasing CD8+ T cell infiltration.
• Synergy with Checkpoint Inhibitors: Combination with anti-PD-1 therapy achieved a 44% long-term survival rate in preclinical studies.
• Potential for Lower Doses: High potency may reduce required dosage and associated side effects.
• Strong Preclinical Safety Profile: No compromise in safety observed in animal models.

Applications

• Cancer treatments
• Immunotherapy combinations

Patent Status

• WO2018213412A1 - Recombinant oncolytic virus - Google Patents (Issued in China and US, pending in EP)

Publications

Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance - PubMed